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INTRODUCTION 
INTRODUCTION
PostPartum Hemorrhage (PPH) is a nightmare even to the present day obstetrician 
as it is sudden, often unpredictable and the consequences may be catastrophic. The 
introduction of oxytocics in the prevention and management of PPH, has contributed to 
the reduction in maternal mortality rate (Moir 1955).1
PPH is the leading cause of matemal deaths in the developing world, responsible 
for 25 percent of all global deaths. Thus worldwide 125,000 women die due to 
Postpartum Hemorrhage.
The primary aim in the management of PPH should  be its prevention. Hence any 
means of reducing the blood loss in the third stage without considerable side effect is 
always welcome.
Uterine atony remains the most common cause of postpartum hemorrhage. A 
review of major causes in postpartum bleeding pointed out uterine atony as the 
aetiology in 81% of PPH cases (Anjaneyulu et al., 1988). 2 Hence adequate contraction 
and retraction of uterus is essential for the prevention of  Post Partum Hemorrhage.
Routine administration of oxytocics reduce the risk of postpartum hemorrhage by 
40% (prendivilli et al 1988).3
The drugs commonly used in the active management of third stage of labour are 
1. Oxytocin
2,   Methyl ergometrine
3.  15 methyl PGF2α 
4.  Misoprostol. 
. REVIEW OF
         LITERATURE
REVIEW OF LITERATURE
Prendivillie et al in Bristol, in their trial of third stage management, found an 
incidence of postpartum bleeding of 5.9% in actively managed group and 17.9% in 
physiologically managed group; they concluded that the active management of third 
stage of labour reduces the risk of postpartum hemorrhage by 30-40% (Prendivillie et al 
1988).5
The objective of prophylactic oxytocics is to ensure effective contraction and 
retraction of the uterus after the delivery of the infant, so as to promote separation and 
descent of the placenta, thus minimizing the amount of blood loss due to failure of 
occlusion of the capillaries in the placental site.
Lister (1950), Martin & Dumoulin (1953) established that intravenous 
ergometrine given with the crowning of the head or anterior shoulder reduces the risk of 
hemorrhage, but has some disadvantages. These were the precise timing of injection 
and the need for second attendant at the time delivery. Embrey (1961) kimbel (1954,58) 
added hyaluronidase to the intramuscular injection to speed up the action of 
ergometrine..
Randomized controlled study, comparing syntometrine i.m  with rectal 
misoprostol 400 mcg showed that the third stage duration, post partum blood loss & 
post partum hemoglobin level were similar in both groups. (Bamingboye, Hofmeyret al 
1998).6
Gerstenfeld TS wing et al, (2001)8 revealed that rectal misoprostol 400mcg was as 
effective as intravenous oxytocin in the prevention of PPH, with no added advantage or 
effectiveness of one over the other. 
Mitchel and elbourne (1993)9 found that syntometrine administered 
intramuscularly concurrent with delivery of the anterior shoulder was more effective 
than oxytocin (5 units i.m) alone in the prevention of post partum hemorrhage.
Villar and colleagues (2002) 10reviewed prophylactic use of misoprostol to prevent 
postpartum haemorrhage and concluded that oxytocin and ergot preparations are more 
effective.
Routine active management was shown to be superior to expectant management 
in that there was statistically significant reduction in the incidence of PPH, postpartum 
matemal hemoglobin of less than 9gm/dl, postnatal blood transfusions, the need for 
therapeutic oxytocics and the third stage lasting more than 20 minutes. These findings 
were confirmed in general population and also in women considered to be at low risk 
for third stage complications. (Prendivillie et al 2002).
In the Dublin trial, complications like increase in diastolic blood pressure greater 
than 100 mmHg, maternal nausea, vomiting and headache were more common in the 
active management group (Begley 1990), but in the Bristol trial they were more 
common in the expectant management group (prendivillie et al 1988). Rogers et al 
199813 trial found no difference in the two groups.
Cochrane database systematic review 20067 concluded that the active management 
is superior to expectant management in terms of blood loss and other serious 
complications of third stage. It is however noticed that an increased incidence of 
unpleasant sideeffects like hypertension and vomiting are when ergometrine is used. 
Still, active management should be made as routine in the management of third stage of 
labour in all institutions. 
a) THE THIRD STAGE OF LABOUR
The third stage of labour is the period from the delivery of the baby until the 
delivery of the placenta. Following the excitement of the birth of the baby, delivery of 
the placenta is often viewed as dull and unimportant. However, management of this 
stage can directly influence important maternal outcomes such as Postpartum 
Hemorrhage and the need for manual removal of the placenta.. 
The mean length of third stage to labour is 6 minutes and the ninety seventh 
percentile is 3 minutes.14
PHYSIOLOGY
Recognition of the physiological events taking place during normal labour is 
important in the correct management of obstetric complications. At term the normal 
volume of blood flow through the placenta is 500- 800ml per minute.15 At placental 
separation, this has to be arrested within seconds. Otherwise serious hemorrhage will 
occur. 
Picture 0
MUSCLE FIBRES OF THE UTERUS - LIVING LIGATURE
     
MECHANISM OF PLACENTAL SEPARATION
Duncan’s Mechanism                      Schultze’s Mechanism
There are three interrelated physiological mechanisms for this:
1)  Contraction and Retraction of the oblique uterine muscle fibres in the upper uterine 
wall, which are arranged in criss cross manner, with vessels intertwined between them 
act as –LIVING LIGATURE, minimizing the blood loss. 
2)  Following separation, the strong uterine contraction brings the uterine walls into 
apposition so that further pressure is exerted on the placental site,so that the torn vessels 
are occluded by themselves.
3) There is increased activation of the coagulation and fibrinolytic system around the 
placental site so clot formation in the torn vessels is intensified.
The main uterotonics  responsible for uterine contraction are oxytocin & 
prostaglandins.16 
PHENOMENA OF THE THIRD STAGE
1) Characteristic uterine contractions. 
2) Separation of the placenta
               a)     Schultze mechanism
               b)     Duncan mechanism
3) Expulsion of the placenta
4) Control of hemorrhage
5) Permanent contraction & retraction of the uterus
Normal blood loss doesn’t exceed 250ml.
PLACENTAL SEPARATION   -     SIGNS & SYMPTOMS
1) Patient complains of pains associated with contraction . 
2) There will be slight amount of  fresh vaginal  bleeding.
3) Extravulval portion of the cord lengthens.
4) Fundus of the uterus rises  above the umbilicus.
5)  Soft elevation above the symphysis with a depression immediately above indicating 
placenta has been separated and is lying in the lower uterine segment.
6)  If  fundus of the uterus is gently grapsed & raised, the cord will not recede, if the 
placenta has separated. Whereas if the placenta is still adherent to the uterus, the portion 
of the cord just outside the vulva will be drawn into the vagina.
Brandt Andrew Technique of the delivery of the placentas
PHYSIOLOGICAL OR EXPECTANT MANAGEMENT OF THIRD STAGE OF 
LABOUR
It involves waiting for signs of separation and allowing the placenta to expel 
spontaneously or aided by gravity or nipple stimulation  (Manually or by breast 
feeding).
1) No uterotonic until after the delivery  of the placenta.
2) No cord traction.
3) Cord is clamped after cessation of pulsation.(Roger J,Wood J et al, 
1998).17
ACTIVE MANAGEMENT OF THE THIRD STAGE OF LABOUR
It was first described by Thilaganathan and colleagues in 1993.18
The management includes,
1) Prophylactic use of  oxytocic  drug. 
2) Early cord clamping  which  reduces the duration of third stage 
(Enkin et al 1995).19 
3) Controlled cord traction 
 -Brandt Andrew technique of the delivery of the placenta. 
4)  Fungal massage
Disadvantages
There is an increased incidence of retained placenta (1-2%) and consequent 
increase incidence of manual removal. 
Advantages
1. Reduces  blood loss approximately  to one fifth of normal blood loss
2. Shortens  the duration of third stage to one half of the normal duration
 ABNORMALITIES OF THIRD STAGE OF LABOUR       
 1)  Retained Placenta
2)   Inversion of uterus.  
3)    Postpartum Hemorrhage.
b)  POSTPARTUM  HEMORRAHAGE
  
Defined as the blood loss of 500ml or more following  vaginal delivery and 
1000ml  or  more  following  Caesarean  Section. 
Primary PPH – Occur with in first 24 hrs after delivery.
Secondary PPH – Loss of blood from the genital tract after 24hrs postpartum and 
within 6wks of delivery.  
Postpartum hemorrhage occurs in 2-11% of deliveries (Gilbert et al 1987, 20 Brant 
1967: 21Newton et al 1961, 22 but in many instances, when blood loss is estimated 
visually, it is underestimated (Gilbert et al 1987).Quantitative measurement of blood 
loss increase the PPH rate to 20%(Newton et al 1961) but life threatening hemorrhage 
occurs in approximately 1 per 1000 deliveries (Lewis and Drife 1998).
Pritchard and associates (1962) found that 5 percent of women delivering 
vaginally lost more than 1000ml of blood. They also observed that the estimated blood 
loss is commonly only about half the actual loss in most cases.
ACOG   defines PPH as blood loss which decreases the haematocrit by 10 percent 
or needs blood transfusion.
FACTORS PREDISPOSING TO POSTPARTUM HEMORRHAGE
1) Uterine Atony: 
               Accounts for 70- 80% of cases of PPH
 Prolonged labour
 Uterine overdistension (large fetus, twins, hydramnios)
 Antepartum  Hemorrhage
 Precipitate labour
 General anaesthesia
 Uterine fibroids
 High parity 
 Excessive or prolonged use of oxytocics in labour
 Magnesium sulphate in labouring patient.  
 Uterine atony in previous   pregnancy 
 Chorioamnionitis 
2) Retained Placenta:
 Uterine fibroids
 Previous caesarean delivery
 Previous curettage
 Excessive handling of uterus  prior to separation
3) Laceration of birth canal
 Precipitous labour
 Instrumental delivery
 Breech extraction 
 Delivery of large baby
4) Coagulation disorder :
 Anticoagulant therapy
 Abruptio placentae
 Intrauterine fetal death
 Amniotic fluid embolism
 Hemorrhagic shock
 Infection – Septicemia
 Coagulation disorder eg. Thrombocytopenia.
CLINICAL DIAGNOSIS
Signs and symptoms are related to the amount of blood loss
Parameter Class I Class II Class III Class IV
1. Blood volume loss 
%
<15 15-30 30-40 >40
 (ml) <750 ml 750-1500 1500-2000 >2000
2. Heart rate
No Change Tachycardia
Moderate
Tachycardia
Marked
Tachycardia
3. Respiration
No change Tachypnoea Tachypnoea
Marked 
Tachypnoea
4. Urine output ml/hr
>30 20-30 5-15 Anuria
5. Mental status Normal Anxious Confused Obtunded
Prophylactic Measures
The primary aim of the obstetrician in the management of PPH should be 
prediction and prevention.
During Pregnancy
i. Women at high risk of PPH should be identified & referred to tertiary care 
centre for delivery.
ii. Anemia in the antenatal period should be prevented with iron 
supplementation.
During Labour
i.  Patients deemed to be  at high risk of PPH, at the onset of labour should have 
blood taken for hemoglobin estimation, grouping, Rh typing & crossmatching, so 
that blood will be available when needed at short notice. 
ii.  Active management of third stage of labour.
Management of Primary Post Partum Hemorrhage
Early detection of PPH and effective blood replacement – the first    step towards 
good management (Hayaishi 1982).25
It requires multidisciplinary team management. It involves simultaneous 
resuscitation of the patient and identification of the cause and instituting definite 
treatment.
RESUSCITATION
 Quick Assessment of the general condition, blood loss and call for assistance.
 Two IV lines with large bore  cannula should be started with colloid (hemacel, 
gelo fusine) running stat through one line and  crystalloids (Hartmann’s 0.9 
percent saline) through the other, till blood arrives. 
 Nasal O2 6-8 litres of 100% oxygen through mask.
 Bladder  to be catheterized.
 Transfusion of blood and blood products
 Monitoring of vital parameters
ESTABLISHING A CAUSE:
It should be done in parallel to stabilization.
1. Check contractility of the uterus.
2. Rechecking the entirety of the Placenta and membranes. 
3. Exploration of the genital tract  to rule out  traumatic  cause.
I   UTERINE ATONY
     - Accounts for the majority of cases of PPH (70- 80%). 
     - It occurs when the uterine corpus fails to contract and retract following delivery. 
Thereby permitting continued blood loss from the placental site (Haysashi 1982) 
immediately after delivery of the infant and placenta. Uterine bleeding, associated with a 
soft, boggy uterus on palpation is characteristic of uterine atony. Often the uterus will 
relax with recurrent bleeding, once massage is discontinued. (Pritchard et al 1985, 
Whitfield 1986).
                                 Bimanual Compression of the Uterus 
TREATMENT
1.  UTEROTONIC AGENT
a) Intravenous Methergine 0.2mg unless contraindicated every 2-4 hrs maximum dose 
0.6mg
b) A drip containing 20units of Oxytocin in 1000 ml of Ringer Lactate or Normal 
Saline, administrated intravenously at 10ml /min.
c) 15-methylderivative of Prostaglandin F2alpha (carboprost tromethamine) 250mcg 
every 15 to 90 minute maximum of eight doses.
d) Prostaglandin E1 analogue T.Misoprostol 1000mcg transrectally.
2.  NON SURGICAL METHODS
a) Bimanual compression of the uterus:
One whole hand is introduced into the vagina with the fingers aligned like cone. 
This hand in the vagina is placed in the anterior fornix while the other hand on the 
abdomen brings the uterus over the fist in the vagina so that the uterine walls are 
compressed. The procedure continues until the uterus becomes contracted and hard. 
b)  Uterine Packing: 
     i)  24F Foley’s catheter (30 ml balloon) distended with 60-80ml   of    saline 
     ii)    Gauze rolls.         
3. SURGICAL METHODS
1. Uterine Brace sutures: B- Lynch suture
2. Hemostatic Multiple square suturing technique
3. Uterine artery ligation
4. Infundibulopelvic vessel ligation 
5. Internal Iliac artery ligation
6. Arterial embolisation
7. Hysterectomy
II.   RETAINED PLACENTA
        Defined as failure of the placenta to be separated and expelled within 30 minutes 
of delivery of  the baby.
 
Treatment
An infusion of oxytocin (40 IU in 500 ml 0.9% saline at a rate of 125 ml/hr) is set 
up
i) To maintain uterine contraction.
ii) To facilitate manual removal of placenta under anesthesia.
III INJURIES TO THE GENITAL TRACT
      Optimal repair of the genital tract lacerations requires correct positioning of the 
patient, satisfactory analgesic anesthesia, adequate lighting and exposures, along with 
appropriate assistance and instruments, preferably in an operation theatre.
IV ACUTE INVERSION OF THE UTERUS
 - The uterus being turned inside out may occur immediately after delivery. It is 
brought about either by pressure from above or by traction from below, in the 
presence of an atonic uterus and a soft dilated os.
 Treatment
           1.   Manual repositioning of the uterus.
            2.   O’ sullivans hydrostatic method.
            3.    Abdominal approach.
                      a) Huntington’s method.  
                       b)  Haultain’s technique.
C) PHARMACOLOGY OF DRUGS:
Drug Onset of action Mode of action
1) Ergometrine 
im 
iv
7min 
20-40sec
More prolonged tetanic 
contraction
2) Oxytocin 
im
iv
3 minutes
immediately
Induces rhythmic 
contraction of uterus
3) Syntometrine 
im 2 minutes
Induces rhythmic & 
tetanic  contraction
4) PGE1, misoprostol 
      oral 
      
      rectal
2 minutes  peaking 
between12-30 minutes
Slow, peaking 
between  1-2hrs
Myometrial contraction
5) PGF2 α 
im 5 minutes 
Myometrial contraction 
and vasoconstriction 
METHRGINE
 Chemical Name: Methyl Ergonovine  maleate
 Semisynthetic  ergot alkaloid used for prevention  and control of   PPH
 Chemically methyl Ergonovine  maleate is designated as ergoline – 8- 
cargboxam 9,10, didehydro –N (1- Hydroxy methyl)Propyl) 6- Methyl – [8 B(S)] 
– (Z)-2 butemaleate.
 O.2 mg in 1ml ampoule im/iv
Clinical pharmacology
               It acts directly on smooth muscle of the uterus and increases  the tone, rate and 
amplitude of rhythmic contractions; induces rapid and sustained tetanic uterotonic 
effect which shortens the third stage duration and blood loss.
 
PHARMACOKINETICS
On IV route, it is rapidly distributed from plasma to peripheral tissue in 2-3 
minutes or less 
Eliminated by hepatic metabolism
ONSET OF ACTION 
IV- immediately (30-40sec)
IM- 2-5 minutes
Oral – 5-10 minutes 
CONTRA INDICATIONS
- Hypertension
- Toxemia
- Hypersensitivity
- Liver, vascular & renal disease
Cardiac disease.
Adverse Effects
      - Nausea, vomiting 
      - Headache
      - Hypertension with seizures
Rarely - Myocardial infarction, transitent chest pain, arterial spasm, tachycardia, 
dyspnoea, thrombophebitis. 
Stored at 2-8˚C, protected form light, (De Groot 1995)26 loses 90% of its potency after I 
yr of storage at 21˚C to 25˚C.
OXYTOCIN
-  Is a naturally occurring uterotonic, first reported by Du Vigeaud in 1953 
- Half life – 3.5 minutes
- Route of administration – im or iv
- While intravenous administration provides immediate drug availability, 
Pharmacokinetic data show that even with im route, oxytocin is found in the 
circulation  in the blood within 2-3 minutes  (Gülmezoglu et al 2002)27
- Mode of action- increases the frequency &  amplitude of contraction
- Storage – 15- 30˚c,  protect from freezing .
 
Side effects: 
1) Injudicious use of oxytocin during labour – causes     fetal asphyxia and rupture 
uterus 
2) Water intoxication due to its antidiuretic action (Whaley. And Pritchard,   1963)28
3) Hypotension 
4) Cardiac arrhythmias.
MISOPROSTOL 
Prostaglandins was the name given by von Euler in 1935 to a substance found in 
extract and secretions of the human prostrate and seminal vesicle. They are derived 
form arachidonic  acid.
 PGE1, analogue
Methyl ester of PGE1
Cheap, stable at room temperature long shelf life, easily administered (oral or vaginal 
or rectal)
Absorption of misoprostol is very rapid. oral – 2 minutes, peaking between 12-30 
minutes.
Mechanism of action
1. It binds to both E2 and E3 prostanoid receptor and stimulates muscle 
contraction. 
2. It exerts a protective effect on the gastrointestinal mucosa by increasing mucus 
and bicarbonates ion secretion and also inhibit acid secretion.
Dosage
400mcg- 600mcg  -      prophylactic for PPH 
800- 1000mcg    -       therapeutic for   PPH.    
Pharmacokinetic
Primary site of metabolism is in liver and less that 1% is excreted in urine. So 
dose has to be adjusted in patients with liver disease.29
Side effects 
High temperature, tachycardia, sweating tachypnoea, shivering, vomiting,  and 
diarrhoea.
    AIM OF THE STUDY
AIM OF THE STUDY
To evaluate and compare IV Methergine, IM Oxytocin and Transrectal 
Misoprostol in the Active Management of Third Stage of Labour, with regard to the:
i) Duration of third stage of labour.
ii) Blood loss during the third stage of labour. 
iii)   Occurence of side effects of the drugs.
MATERIALS
&
METHODS
MATERIALS AND METHODS
300 patients  were  included  in the  study.
 100 patients were  allotted  IV  Methergine (0.2 mg) during anterior shoulder 
delivery  under  Group I.
100   patients were allotted   I.M  Oxytocin 10U after delivery of the baby under 
Group II.
 100 patients were allotted Transrectal Misoprostol 600 mcg after delivery of the 
baby under Group III.
Study period (May 2008 –August 2008) 
INCLUSION CRITERIA
1) age 20-35yr
2) >37 wks of gestation
3) Singleton  pregnancy
4) Vertex presentation
5) No fetal distress on admission
EXCLUSION CRITERIA
1) Previous caesarean section
2) Multiple pregnancy
3) Breech presentation
4) Multipara   > 5
5) Intrauterine fetal death
6) Previous scarred uterus ( mymectomy / hysterotomy)      
7)  Cardiac / Renal/ Hepatic/ Epileptic/ Severe PIH/ Severe Anemia
METHOD
Procedure of drug administration 
Group I - Inj Methergine 0.2mg was given intravenously during the delivery of the 
anterior shoulder of the  baby. 
Group II - Inj Oxytocin 10IU im given after the delivery of the baby within a minute. 
Group III- T.Misoprostol 600mcg kept transrectally immediately after the delivery of 
the baby.
Estimation of blood loss
After the delivery of the baby, a blood collecting calibrated drape was placed 
underneath the gluteal region, and tied anteriorly over the abdomen and thighs. The 
collected blood is measured after 1hr of delivery in ml.
 
FACTORS OBSERVED
1) Labour- spontaneous, induced, augmented
2) Duration of 1st, 2nd and 3rd stage of labour
3) Amount of blood loss during 3rd stage of labour
4) Hemoglobin  - before and after delivery
5) BP - 1min and 5 min after drug administration
6) Third stage complications if any 
7) Side effects of the drugs. 
8) Any other uterotonics – needed
9) Treatment of the complications , blood transfusion if any given

TABLE - 1
AGE DISTRIBUTION 
AGE Methergine Oxytocin Misoprostol Total
No. No. No. No. %
20-24yr 80 79 79 238 79.3%
25-30yr 17 14 16 47 15.7%
>30yr 3 7 5 15 5.0%
Total   100 100 100 300 100%
In all the three groups studied 80% of the cases are between 20-24yrs of age.  

TABLE -2
PARITY
PARITY Methergine Oxytocin Misoprostol Total
No. No. No. No. %
Primi 48 42 42 132 44.0%
Gravida 2 37 56 38 131 43.7%
Gravida  3 12 2 18 32 10.7%
Gravida  4 3 0 2 5 1.7%
Total 100 100 100 300 100%
In all the three study groups, primigravidae constitute more than 40%, where as 
Gravida II formed 56% in Oxytocin group & <40% in other groups. 
Gravida III averaged 10.7% & Gravida IV 1.7%.

TABLE-3
BOOKING STATUS
Booking 
Status Methergine Oxytocin Misoprostol Total
No. No. No. No. %
Booked 96 94 94 284 94.7%
Unbooked 4 6 6 16 5.3%
Total 100 100 100 300 100%
More than 90% were booked case in all the three groups.

TABLE-4
SOCIO – ECONOMIC STATUS
S.E.Status Methergine Oxytocin Misoprostol Total
No. No. No. No. %
Class IV 98 94 96 288 96.0%
Class V 2 6 4 12 4.0%
Total 100 100 100 300 100%
 More than 95% of the cases belonged to socio economic status class IV in all the 
three groups. 

TABLE -5
LABOUR
LABOUR Methergine Oxytocin Misoprostol Total
No. No. No No. %
Spontaneous 49 41 54 144 48.0%
Augmented 44 49 35 128 42.7%
Induced 7 10 11 28 9.3%
Total 100 100 100 300 100%
In Group I, spontaneous  onset of labour constitute 49%, augmented  labour -44% 
and induced  labour-7%
In group II, 41% had spontaneous labour -41% augmented labour- 49% and 
Induced labour in  10% of cases. 
In group III, 54% had spontaneous  labour, 35% augmented and 11% induced 
labour.

TABLE-6
MODE OF DELIVERY
Mode Of 
Delivery
Methergine Oxytocin Misoprostol Total
No. No. No. No. %
L.Natural 48 65 56 169 56.3%
L.N LPI˚ 35 25 34 94 31.3%
LN.LPII˚/ 
EPI
15 9 9 33 11.0%
Outlet 
forceps
2 1 1 4 1.3%
Total 100 100 100 300 100%
In all the three groupss, Labour natural constituted above 50-60%, LN with LPI˚ 
constituted 25-35%, LN with LPII˚ / Epi constituted  9-5%, outlet forceps constitute 
around 1-4%. 

TABLE-7
DURATION OF THIRD STAGE OF LABOUR
Duration of
Third stage 
of labour in 
minutes
Methergin
e Oxytocin Misoprostol Total
No. No. No. No. %
0-2 min 1 0 1 2 0.7%
2-4min 95 86 60 238 79.3%
4-6min 5 14 39 58 19.3%
>6min 2 0 0 2 0.7%
Total 100 100 100 300 100%
In group I, duration of third stage of labour was 2-4 min in 92% of the cases. 
In group II duration of 2-4 in 80% of the cases
In group III duration of 2-4Min in 60% of the cases
DURATION OF THIRD STAGE
P=0.117
Not Significant
N Mean Std. Deviation Std. Error
Group I 100 195.1500 135.87066 13.58707
Group II 100 209.3000 26388490 2.68849
Group III 100 242.4600 173.58329 17.35833
Total 300 212.3033 128.7749 7.43093
There is no statistical significance among the means of the Groups pertaining to 
duration of third Stage 

TABLE-8
BLOOD LOSS DURING THIRD STAGE OF LABOUR
BLOOD 
LOSS
Methergine Oxytocin Misoprostol Total
No. No. No. No. %
<100ml 4 3 2 9 3%
100-150ml 80 40 31 151 50.3%
160-200ml 12 51 49 112 37.3%
210-300ml 1 4 15 20 6.7%
310-500ml 1 0 1 2 .7%
>500ml 2 2 2 6 2%
Total 100 100 100 300 100%
Blood loss of 100- 150ml present in 80% of GroupI, 40% of GroupII and 31% of 
group III.
Blood loss of 160-200ml present in 12% of GroupI, 51% of Group II and 49% of 
Group III.  
Mean blood loss in  Group I – 145 ml
                                    Group II - 165 ml
                                      Group III - 178 ml
AMOUNT OF BLOOD LOSS
P=O.OOO
Significant
N Mean Std. deviation Std. Error
Group I 100 145.2000 51.09864 5.10986
Group II 100 165.2000 61.81563 6.18156
Group III 100 178.7900 63.78140 6.37814
Total 300 163.0633 60.56119 3.49650
 There is statistical significance among the means of the three Groups pertaining to 
the blood loss during third stage of labour. 

TABLE -9
OTHER UTEROTONICS USED
Other 
uterotonics
methergine oxytocin Misoprostol Total
No. No. No. No. %
Not used 99 94 92 285 95%
Used 1 6 8 15 5%
Total 100 100 100 300 100%
 
In group I, only one case needed additional uterotonic oxytocin 10 units IV 
infusion. In group II, other uterotonic was used in 6% of the cases  and 8% of the cases 
in group III needed other uterotonics.

TABLE-10
HAEMOGLOBIN DIFFERENCE
Haemoglobin 
Difference
Methergine Oxytocin Misoprostol Total
No. No. No. No. %
<0.5gm 54 38 40 132 44.0%
0.6-1gm 43 61 57 161 53.7%
1-2gm 2 1 2 5 1.7%
>2gm 1 0 1 2 .7%
Total 100 100 100 300 100%
When Hb % was estimated before & after delivery, the fall in Hb%was as 
follows;  
In group I, 54% of the cases had Hb difference of < 0.5 gm.
In group II, 61% of the cases had Hb difference of 0.6-1gm.
In group III 57% of the cases had Hb difference of 0.6-1gm.

TABLE-11
COMPLICATIONS
Complications Methergine Oxytocin Misoprostol TotalNo. No. No. No. %
Nil 97 98 98 293 97.7%
Mild Atonic 
PPH 1 2 2 5 1.7%
Retained 
Placenta 2 0 0 2 .7%
Total 100 100 100 300 100%
In group I, Retained placenta was  seen in  about 2% of the cases & 1 had mild 
atonic  PPH  while  97% had no complication.
In group II and group III, 98% had no complications, but mild atonic PPH was 
noticed in about 2% of the cases.
TABLE-12
SIDE EFFECTS OF THE DRUGS
Side Effects Of 
The Drug
Methergine Oxytocin Misoprostol Total
No. No. No. No. %
Nil 79 100 74 253 84.3%
Nausea 6 0 0 6 2.%
Vomiting 10 0 0 10 3.3%
Diarrhoea 0 0 7 7 2.3%
Shivering 0 0 15 15 5%
Increase in BP 5 0 0 5 1.7%
fever 0 0 4 4 1.3%
Total 100 100 100 300 100%
In group I, the incidence of nausea – 6%, vomiting – 10% and hypertension- 5%.
In group II, there were no maternal side effect.
In group III, the incidence of diarrhoea – 7% shivering -15% and fever in 4% of 
cases. 

TABLE-13
TREATMENT
Treatment Methergine Oxytocin Misoprostol TotalNo. No. No. No. %
Nil 97 98 98 293 97.7%
Medical 
management  of 
atonic PPH & 
blood Transfusion
1 2 2 5 5%
Manual removal 
of placenta & 
blood Transfusion
2 0 0 2 .7%
Total 100 100 100 300 100%
In group I, manual removal of placenta and blood transfusion for retained placenta 
done in 2% of the cases. One case of mild atonic PPH managed medically and with 
blood transfusion.
In group II & III, the incidence of mild atonic PPH managed medically and with 
blood transfusion is 2% 
 DISCUSSION
DISCUSSION
In present study, 80%of the cases were in the age group of 20-24yr, primigravida 
constituted about 40%, and more than 90% were booked cases in all the three groups.
In all the three groups, labour natural was about 50-60%, LN with LPI˚ 25-35%, 
LN with LPII / EPi – 9-15% and outlet forceps constituted 1-4%.
A randomized controlled trial was carried out between Jan 2000 – oct 2000 in the 
maternity unit of the Social Security Association Maternity & Women Health Teaching 
Hospital in Ankara, 34Turkey. 1574 women were grouped into 4. One group receiving 
misoprostol alone; other group receiving misoprostol and oxytocin  10 iv, third group 
receiving oxytocin 10iv alone and fourth group receiving oxytocin infusion and 
methergine 0.2mg im. In their study duration of third stage of labour is misoprostol 
group – 9.2min and in oxytocin group 8.7min. 
In present study, mean duration of third stage of  labour in Methergine group was 
3 min 15 sec, Oxytocin group – 3 min 29 sec and in Misoprostol  group- 4 min 20 sec.
In the Ankara study, blood loss of > 500ml in Misoprostol group – 9%, oxytocin 
group -7.3% and in oxytocin - methergine  combined group - 3.5%.  In present study, 
blood loss of >500ml was 2% in  all the three groups. The incidence of additional 
uterotonics  needed in the above study was  5.9% in misoprostol group, 6.7% in the 
oxytocin group and  1.5% in oxytocin methergine combined group. In present study the 
incidence of additional uterotonics in Methergine  group  was 1%, Oxytocin group- 6% 
and in Misoprostol  group  -8%.
In the Ankara study the need for postpartum blood transfusion was 3.6% in 
misoprostol group, 3.2% in oxytocin group and 1.5% in combined oxytocin & 
methergine group.  In present study, the need for blood transfusion was 3% in 
Methergine group and 2% in both the Oxytocin & Misoprostol groups.
In the above study the incidence of shivering was 11.3% diarrhoea – 3.8% and 
fever in 4.3% in the misoprostol. In present study the incidence of shivering was noted 
jn 15%, diarrhea -7% and fever -4% in Misoprostol group. 
Trials using oxytocin alone showed reduced rate of manual removal of the 
placenta where as those using ergot preparations demonstrated increased rates. This 
trend of slight increase in  manual removal of placenta mentioned in the Cochrane meta 
analysis, was entirely due to the results of the single trial that used ergot iv ( Begley, 
1990) In present study the incidence of retained placenta requiring manual removal was 
2% in  methergine  group only, not  in other groups.
The incidence of  increase in nausea, vomiting  and increase in blood pressure 
were all exclusively observed in the trials using ergot preparations  (Elbourne, 2002). In 
present study, the incidence of nausea was 6%, vomiting – 10% and increase in BP in 
5% in the methergine  group.
Studies undertaken by the WHO favour oxytocin in the active management of 
third stage of labour because it is more stable when exposed to heat & light compared  to 
ergot preparations, which has to be stored at 2-8∙C to retain its potency. This makes 
oxytocin more useful in settings where storage facilities especially refrigerator may be 
an issue.
Oxytocin is the first line of choice for prevention of PPH because it is as effective, 
or  more effective than ergot alkoids or prostaglandins and has fewer side effect. (235,3).
36
Oxytocin is preferred for prevention of PPH in all women to ergometrine, because 
of its similar benefits and reduced adverse effects. In situations where oxytocin or 
ergometrine  are not consistently available  & appropriately used during third stage of 
labour, misoprosrol should be      considered for inclusion in the AMSTL protocol.28
SUMMARY
SUMMARY
 Routine active management is superior to expectant management in terms of 
reduction of blood loss, in preventing PPH and other serious complications of 
third stage of labour.
In present study
 Age group 20-24 yrs constituted  80% 
 40% were primigravida.
 90% were  booked cases and 95% belonged to socio economic status class IV
 Labour natural constituted 50-60% in all the three groups
 Mean duration of third stages of labour in Group I- 3 min 15 sec, 
                                                          GroupII – 3min 29 sec 
                                                          Group III – 4 min 20 sec.
 Mean blood loss during  third stage of labour in 
                                                            Group I - 145ml  
                                                            Group II - 165ml 
                                                            GroupIII. -  178ml
 Incidence of use of other uterotonics in Group I- 1% 
                                                                       GroupII- 6%
                                                                      Group III – 8%.
 Incidence of complications  in– 
                           Group I - 2% of retained placenta, 
                                           1% of mild PPH.
                        Group II& III - 2% mild PPH...
 Incidence of postpartum blood transfusion –
                      Group I- 3%
                      Group II &III -2%
 Side effects  of the  drugs  in
Group I  - Nausea – 6%, Vomiting – 10% & 
Hypertension – 5%.
                  Group II – Nil maternal side effects.
 Group III – Diarrhoea – 7%, Shivering – 15% & fever 
-4
CONCLUSION
CONCLUSION
 Predicting who will have PPH based on risk factors is difficult, because two third 
of women who developed PPH have no risk factors. Therefore all women should 
be considered as at risk for PPH and Hemorrhage prevention must be incorporated 
into the care provided during  every labour. Every woman is at risk for PPH.
 Routine screening to prevent and treat anaemia during pre– conception,  antenatal 
and postpartum  period.
 Counsel women on nutrition, focusing on available iron and folic acid rich foods 
and provide iron and folate supplements during pregnancy.
 Active management of third stage of labour should be made as a routine for each 
& every  labour conducted in an institution. There is need for a Randomized 
controlled trial of active versus expectant management of the third stage of labour 
in different clinical settings such as in domiciliary practice in the developing 
world, where the risk of maternal mortality associated with the third stage of 
labour is very high.
 When ergometrine is used as a compoment of active management, it is associated 
with an increase risk of retained placenta & unpleasant side effects like nausea, 
vomiting and hypertension and has limitations  in its use.
 Oxytocin is the first line of choice for prevention of PPH because it is more 
heat & light stable, as effective as or even more effective than ergot alkoids or 
prostaglandins and has fewer  side effects & infact no side effect was noted in this 
study.
 Misoprostol may be used when other oxytocic agents are not available for the 
prevention of PPH; it is cost effective, heat & light stable, in tablet form and easy 
to use, that can control PPH even without a medically trained attendant.      
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PROFORMA
PROFORMA
Name:     Age:    IP No:
Date of  Admission: Obstetric  Score: G  P  L  A
Date of  Delivery:     LMP :
Date of  Discharge:       EDD :     
Booked / Unbooked:               Socio Economic Status: 
Menstrual History :
 Marital  History :
 Obstetric History :    1.
                                   2.
                                   3.
                                    4.
O/E: Anemic / Not anemic
PR: BP:             CVS:      RS:
Risk  Factors :
Labour:
1. Spontaneous   2. Induced           3. Augmented
a) ARM 
b) Oxytocin 
c) Both
Duration  of   First  Stage:                     Second  stage;
Mode Of Delivery:
a) Spontaneous vaginal Delivery:  1. Labour Natural, 
2. L. N. with LP Iº 
3. L.N. with LP IIº  
b) .Low  Midcavity  Forceps. 
c)  Outlet Forceps.
Method Used In Third Stage Management:
Group I  -   IV methergine 0.2 mg during anterior shoulder delivery.
Group II -  IM oxytocin 10 U after delivery of the baby.
      Group III  - Transrectal Misoprostol 600 micro g after delivery of the 
                          baby
Duration of Third stage: -------min -----sec
Amount of Blood Loss during Third Stage:  --------ml
BP 1 min and 5 min after drug administration 
Baby Details:
Haemoglobin in grams:   a) Before Delivery
              b) After Delivery
Complications if any:
Material Side Effect of the Drug:
Treatment of the complications:                                 Blood Transfusion:
ABBREVIATIONS
PPH - Post Partum Hemorrhage
L.N - Labour Natural 
LP I˚ -  Lacerated perineum first degree
LP II˚ - Lacerated perineum second degree
Epi - Episiotomy
µg/ mcg - Microgram
mg - Milligram
IU - International unit
AMSTL - Active Management of Third Stage of Labour 
WHO - World Health Organization 
im - Intramuscular 
iv - intravenous 
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